Beacon Biosignals Raises $11M Series B Extension for AI Brain Health Diagnostics
Summary
Beacon Biosignals has raised an $11 million extension to its Series B financing, bringing the total Series B to over $97 million and total funding to more than $121 million. Beacon's FDA-cleared Waveband device directly measures brain electrical activity via EEG during sleep and wake, bringing gold-standard neurophysiology into patients' homes. The company's foundation model is trained on millions of hours of EEG to uncover early disease signatures and predict treatment response, supporting R&D programs with more than half of the world's top ten biopharmaceutical companies.
Why it matters
This extension reflects continued investor confidence in AI-driven neurodiagnostics at a time when neurology and psychiatry still lack the objective biomarkers that revolutionized other areas of medicine. Beacon's approach of combining real-world sleep EEG data with foundation models trained at massive scale could transform drug development and patient care in CNS disorders. The participation of both technology and pharmaceutical investors signals that neurodiagnostic platforms are viewed as infrastructure for precision neuroscience.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial